Eravacycline

CHEMBL1951095 Phase 4 Aprovado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
558.6 g/mol
LogP
1.0
Phase
4

This broad-spectrum tetracycline antibiotic works by blocking the machinery that bacteria use to make proteins, stopping them from growing and reproducing. It is used to treat complicated intra-abdominal infections caused by resistant bacteria.

Peso Molecular

558,6000 g/mol

LogP

1,00

TPSA

194,00 Ų

Regra dos 5 de Lipinski

Reprovado

Mecanismo de Ação

Binds reversibly to the 30S ribosomal subunit, blocking the attachment of aminoacyl-tRNA to the ribosomal acceptor (A) site. This inhibits bacterial protein synthesis in a bacteriostatic manner.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Binds reversibly to the 30S ribosomal subunit, blocking the attachment of aminoacyl-tRNA to the ribosomal acceptor (A) site. This inhibits bacterial protein synthesis in a bacteriostatic manner.

Estrutura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)c(NC(=O)CN5CCCC5)cc(F)c4C[C@H]3C[C@@H]12

InChI

InChI=1S/C27H31FN4O8/c1-31(2)20-13-8-11-7-12-14(28)9-15(30-16(33)10-32-5-3-4-6-32)21(34)18(12)22(35)17(11)24(37)27(13,40)25(38)19(23(20)36)26(29)39/h9,11,13,20,34,36-37,40H,3-8,10H2,1-2H3,(H2,29,39)(H,30,33)/t11-,13-,20-,27-/m0/s1

Molecular Formula

C27H31FN4O8

HBD / HBA

6 / 11

Ligações Rotacionáveis

5

Átomos Pesados

40

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

This broad-spectrum tetracycline antibiotic works by blocking the machinery that bacteria use to make proteins, stopping them from growing and reproducing. It is used to treat complicated intra-abdominal infections caused by resistant bacteria.

Binds reversibly to the 30S ribosomal subunit, blocking the attachment of aminoacyl-tRNA to the ribosomal acceptor (A) site. This inhibits bacterial protein synthesis in a bacteriostatic manner.

Yes, Eravacycline is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1951095. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 54726192. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.